Deans' stroke musings: Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers

Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Monday, May 27, 2024

Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers

In case you have an aneurysm you can ask your doctor about this possibility. Your doctor just might be competent if s/he knows what you're talking about when you mention this.

Contour Neurovascular System for endovascular embolization of cerebral aneurysms: a multicenter cohort study of 10 European neurovascular centers

http://orcid.org/0000-0002-2952-3812Christoph J Griessenauer1,
http://orcid.org/0000-0001-5629-3023Sherief Ghozy2,
http://orcid.org/0000-0002-3185-0740Alessandra Biondi3,4,
http://orcid.org/0000-0003-0521-8570Constantin Hecker1,5,
http://orcid.org/0000-0003-1413-2699Fritz Wodarg6,
http://orcid.org/0000-0001-5640-7780Thomas Liebig7,
Tufail Patankar8,
Saleh Lamin9,
http://orcid.org/0000-0002-8024-4712Mario Martínez-Galdámez10,11,
http://orcid.org/0000-0003-4287-2627Christophe Cognard12,
http://orcid.org/0000-0001-8533-7478Jens Fiehler13,
Franziska Dorn14,
http://orcid.org/0000-0003-0131-5699Adam A Dmytriw15,16,
http://orcid.org/0000-0001-5572-7694Monika Killer-Oberpfalzer5,17

Correspondence to Dr Christoph J Griessenauer, Department of Neurosurgery, Christian Doppler Clinic, Paracelsus Medical University, Salzburg, Austria; christoph.griessenauer@gmail.com

Abstract

Background Intrasaccular devices have become increasingly popular in the treatment of cerebral aneurysms, particularly at the bifurcation. Here we evaluate the Contour Neurovascular System, an intrasaccular device for the endovascular treatment of cerebral aneurysms, in a multicenter cohort study, the largest to the best of our knowledge.

Methods Consecutive patients with intracranial aneurysms treated with the Contour Neurovascular System between February 2017 and October 2022 at 10 European neurovascular centers were prospectively collected and retrospectively reviewed. Patient and aneurysm characteristics, procedural details, and angiographic and clinical outcomes were evaluated.

Results During the study period, 279 aneurysms (median age of patients 60 years, IQR 52–68) were treated with Contour. In 83.2% of patients the device was placed electively, whereas the remaining patients were treated in the setting of acute subarachnoid hemorrhage. The most common locations were the middle cerebral artery (26.5%) followed by the anterior communicating region (26.2%). Median aneurysm dome and neck size were 5.2 mm (IQR 4.2–7) and 3.9 mm (IQR 3–5). Contour size 7 (39%) and 9 (25%) were most used. Thromboembolic and hemorrhagic complications occurred in 6.8% and 0.4% of aneurysms, respectively. Raymond-Roy 1 and 2 occlusions at last follow-up were achieved in 63.2% and 28.3%, respectively, resulting in adequate occlusion of 91.5% of aneurysms.

Conclusion This is the largest multicenter study reporting the outcome on the Contour Neurovascular System. At 1 year, the self-evaluated data on safety and efficacy are comparable to data of existing intrasaccular devices. Contour is a promising technology in the treatment of cerebral aneurysms.